Clinical Research
Dr. Wong participates in international clinical trials as a site principal investigator, bringing access to investigational therapies to patients at Asia Pacific Eye Centre, Gleneagles Hospital, Singapore.
Dr. Wong's research role
As a site PI, Dr. Wong is responsible for the conduct of clinical trials at Asia Pacific Eye Centre in accordance with ICH Good Clinical Practice guidelines. This includes patient recruitment and consent, protocol adherence, safety monitoring, and data integrity. Participation in trials is entirely voluntary and does not affect access to standard clinical care.
Trials
Current & recent studies
The following trial has been conducted at this site. Recruitment is now closed, but patients with pathologic myopia are encouraged to speak with Dr. Wong about current treatment options and any future study opportunities.
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia
Investigational drug
Faricimab (Vabysmo) 6 mg, intravitreal injection — a bispecific antibody targeting both VEGF-A and Ang-2
Comparator
Ranibizumab 0.5 mg, intravitreal injection — standard-of-care anti-VEGF agent
Condition studied
Choroidal neovascularisation (CNV) secondary to pathologic myopia, in treatment-naïve patients
Study design
Randomized, triple-masked, parallel-group, active-comparator controlled. Pro re nata (as-needed) dosing after loading injection.
Primary endpoint
Change in best-corrected visual acuity (BCVA, ETDRS letters) averaged over weeks 4, 8, and 12 from baseline
Enrolled / timeline
280 participants globally · Study start: March 2024 · Primary completion: September 2025 · Final completion: May 2026
Key eligibility criteria
Recruitment for the POYANG study is now closed. If you have pathologic myopia with suspected CNV, please book a consultation. Dr. Wong can assess your condition and discuss all available treatment options, including any new trials that may open in future.
About clinical trials
What participation involves
Clinical trial participants receive close monitoring and access to investigational treatments at no cost. Participation is always voluntary — you can withdraw at any time without it affecting your regular care.
You will be assessed to confirm eligibility. A study coordinator will explain the protocol, risks, and benefits in detail. You will have time to consider before signing a consent form.
You will receive either the investigational drug or an approved comparator, with scheduled clinic visits for assessments including visual acuity testing and retinal imaging.
The study team monitors your response and safety throughout. Any side effects are recorded and reported. You may withdraw from the trial at any time, for any reason.
If you have a retinal condition and are interested in being considered for future studies, contact the clinic. We can discuss whether your condition may make you eligible for upcoming trials and keep you informed as new studies open.
Phone / WhatsApp
Location
Asia Pacific Eye Centre
Gleneagles Hospital, Singapore
Clinic hours
Mon – Fri: 9am – 5pm
Sat: 9am – 1pm